CARA
Cara Therapeutics Inc
1 day chart
About CARA
Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).
Buy US stocks in Australia starting with CARA. Open an account and start investing today!
$185.70M
-
0.00%
183.74K
$3.45
$3.29
$3.42
$12.98
$3.24
CARA FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CARA
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.